407 related articles for article (PubMed ID: 18590496)
1. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
2. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
3. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
[TBL] [Abstract][Full Text] [Related]
7. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
8. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.
Devyatko E; Zuckermann A; Ruzicka M; Bohdjalian A; Wieselthaler G; Rödler S; Wolner E; Grimm M
J Heart Lung Transplant; 2004 Nov; 23(11):1277-82. PubMed ID: 15539126
[TBL] [Abstract][Full Text] [Related]
9. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
10. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
Bedel AN; Hemmelgarn TS; Kohli R
Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
[TBL] [Abstract][Full Text] [Related]
15. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.
Helanterä I; Lautenschlager I; Koskinen P
Nephrol Dial Transplant; 2009 Jan; 24(1):316-20. PubMed ID: 18842670
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
17. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
18. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
Sagedal S; Nordal KP; Hartmann A; Midtvedt K; Foss A; Asberg A; Degré M; Fauchald P; Rollag H
Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
